BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 10490736)

  • 1. Costs of care associated with high-dose therapy and autologous transplantation for non-Hodgkin's lymphoma: results from the University of Nebraska Medical Center 1989 to 1995.
    Freeman M; Vose J; Bennett C; Anderson J; Kessinger A; Turner K; Pierson J; Bishop M; Bierman P; Armitage J
    Bone Marrow Transplant; 1999 Sep; 24(6):679-84. PubMed ID: 10490736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GM-CSF versus G-CSF: engraftment characteristics, resource utilization, and cost following autologous PBSC transplantation.
    Zumberg MS; Leather HL; Nejame C; Meyer C; Wingard JR
    Cytotherapy; 2002; 4(6):531-8. PubMed ID: 12568989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs of care and outcomes for high-dose therapy and autologous transplantation for lymphoid malignancies: results from the University of Nebraska 1987 through 1991.
    Bennett CL; Armitage JL; Armitage GO; Vose JM; Bierman PJ; Armitage JO; Anderson JR
    J Clin Oncol; 1995 Apr; 13(4):969-73. PubMed ID: 7707125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy.
    Molina A; Krishnan AY; Nademanee A; Zabner R; Sniecinski I; Zaia J; Forman SJ
    Cancer; 2000 Aug; 89(3):680-9. PubMed ID: 10931469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation.
    Bierman PJ; Sweetenham JW; Loberiza FR; Taghipour G; Lazarus HM; Rizzo JD; Schmitz N; van Besien K; Vose JM; Horowitz M; Goldstone A;
    J Clin Oncol; 2003 Oct; 21(20):3744-53. PubMed ID: 12963703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost comparative study of autologous peripheral blood progenitor cells (PBPC) and bone marrow (ABM) transplantations for non-Hodgkin's lymphoma patients.
    Woronoff-Lemsi MC; Arveux P; Limat S; Deconinck E; Morel P; Cahn JY
    Bone Marrow Transplant; 1997 Dec; 20(11):975-82. PubMed ID: 9422478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A multicenter early phase II study of high-dose chemotherapy with autologous peripheral blood stem cell transplantation for treatment of intermediate-grade non-Hodgkin's lymphoma. Japan Blood Cell Transplantation Study Group].
    Chou T; Ishiguro T; Imajo K; Kawano F; Gondo H; Kasai M; Masuda M; Koike M; Shimazaki C; Hara M; Shinagawa K; Ogawa M; Takaku F; Harada M
    Rinsho Ketsueki; 1999 Oct; 40(10):1058-67. PubMed ID: 10565222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tandem transplant of peripheral blood stem cells for patients with poor-prognosis Hodgkins's disease or non-Hodgkin's lymphoma.
    Fitoussi O; Simon D; Brice P; Makke J; Scrobohaci ML; Bibi Triki T; Hennequin C; Fermé C; Gisselbrecht C
    Bone Marrow Transplant; 1999 Oct; 24(7):747-55. PubMed ID: 10516678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct hospital resource utilization and costs of treating patients with multiple myeloma in Southwest Sweden: a 5-year retrospective analysis.
    Ghatnekar O; Alvegård T; Conradi N; Lenhoff S; Mellqvist UH; Persson U; Löthgren M
    Clin Ther; 2008 Sep; 30(9):1704-13. PubMed ID: 18840377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial results.
    Elting LS; Shih YC; Stiff PJ; Bensinger W; Cantor SB; Cooksley C; Spielberger R; Emmanoulides C
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):806-13. PubMed ID: 17580258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (>/=60 years) with non-Hodgkin's lymphoma: comparison with patients <60 years treated within the same protocol.
    Jantunen E; Mahlamäki E; Nousiainen T
    Bone Marrow Transplant; 2000 Oct; 26(7):737-41. PubMed ID: 11042654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma.
    Cremerius U; Fabry U; Wildberger JE; Zimny M; Reinartz P; Nowak B; Schaefer W; Buell U; Osieka R
    Bone Marrow Transplant; 2002 Jul; 30(2):103-11. PubMed ID: 12132049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost determinants in aggressive non-Hodgkin's lymphoma.
    van Agthoven M; Sonneveld P; Verdonck LF; Uyl-de Groot CA
    Haematologica; 2005 May; 90(5):661-71. PubMed ID: 15921381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective analysis of 144 patients with aggressive non-Hodgkin's lymphoma: impact of autologous stem cell transplantation in first remission on outcome.
    Fanin R; Sperotto A; Ruiz De Elvira C; Zaja F; Stocchi R; Geromin A; Cerno M; Patriarca F; Fanni Canelles M; Damiani D; Baccarani M
    Haematologica; 2000 Sep; 85(9):943-51. PubMed ID: 10980633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced charges and costs associated with outpatient autologous stem cell transplantation.
    Meisenberg BR; Ferran K; Hollenbach K; Brehm T; Jollon J; Piro LD
    Bone Marrow Transplant; 1998 May; 21(9):927-32. PubMed ID: 9613786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.
    van Imhoff GW; van der Holt B; Mackenzie MA; Van't Veer MB; Wijermans PW; Ossenkoppele GJ; Schouten HC; Sonneveld P; Steijaert MM; Kluin PM; Kluin-Nelemans HC; Verdonck LF;
    J Clin Oncol; 2005 Jun; 23(16):3793-801. PubMed ID: 15809447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bottom-up analysis of the case costs of stem cell transplantation and selected chemotherapies].
    Stäbler W; Wagner B
    Klin Padiatr; 2003; 215(3):179-84. PubMed ID: 12778360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [High-dose chemotherapy with autologous peripheral blood stem cell transplantation for treatment of non-Hodgkin's lymphoma].
    Yamane T; Hino M; Ohta K; Koh KR; Nakamae H; Aoyama Y; Ota T; Kishida T; Mugitani A; Sannomiya Y; Kamitani T; Takubo T; Tatsumi N
    Gan To Kagaku Ryoho; 2000 Sep; 27(10):1547-55. PubMed ID: 11016000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health care resource use associated with integrated psychological treatment.
    Vasiliadis HM; Briand C; Lesage A; Reinharz D; Stip E; Nicole L; Lalonde P
    J Ment Health Policy Econ; 2006 Dec; 9(4):201-7. PubMed ID: 17200597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.